Bisphosphonates Not Linked to Esophageal Cancer, Says Study

Yes, they are - they are "possibly" linked.

Oral bisphosphonates are not significantly associated with esophageal or gastric cancer, according to a large cohort study from the United Kingdom published in the August 11 issue of the Journal of the American Medical Association.

The new study comes out about a year and a half after the US Food and Drug Administration (FDA) reported 23 cases of esophageal cancer between 1995 and 2008 in patients using alendronate and another 31 cases in patients using a variety of bisphosphonates in Europe and Japan.

These cases "possibly" indicate "risk of malignancy associated with bisphosphonate use," note the authors of the new study.

The authors took up the challenge of investigating the possible link between these cancers and oral bisphosphonates, the use of which has "dramatically" increased in recent years in the Western world.

The link was not proven in 2 recent smaller studies, say the authors, led by Chris Cardwell, PhD, from the Center for Public Health at Queen's University in Belfast, Northern Ireland.

The lack of a link to cancer stands in contrast to the proven link between the use of oral bisphosphonates and esophagitis.

Better not to need these drugs at all.

Read up on how and then go to Anabolic Clinic to learn more.